Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy

被引:0
|
作者
Jing Yuan
Li Xu
Hai-Juan Bao
Jie-lin Wang
Yang Zhao
Shuo Chen
机构
[1] The Third Affiliated Hospital of Guangzhou Medical University,Department of Obstetrics and Gynecology, Department of Gynecologic Oncology Research Office, Guangzhou Key Laboratory of Targeted Therapy for Gynecologic Oncology, Guangdong Provincial Key Labor
[2] The First Hospital of China Medical University,Department of Laboratory Medicine
关键词
A-to-I editing; Innate immunity; Cell death; Targeted therapy; Cancer immunotherapy;
D O I
暂无
中图分类号
学科分类号
摘要
Adenosine-to-inosine (A-to-I) editing, a key RNA modification widely found in eukaryotes, is catalyzed by adenosine deaminases acting on RNA (ADARs). Such RNA editing destabilizes endogenous dsRNAs, which are subsequently recognized by the sensors of innate immune and other proteins as autologous dsRNAs. This prevents the activation of innate immunity and type I interferon-mediated responses, thereby reducing the downstream cell death induced by the activation of the innate immune sensing system. ADARs-mediated editing can also occur in mRNAs and non-coding RNAs (ncRNAs) in different species. In mRNAs, A-to-I editing may lead to missense mutations and the selective splicing of coding regions. Meanwhile, in ncRNAs, A-to-I editing may affect targeting and disrupt ncRNAs maturation, leading to anomalous cell proliferation, invasion, and responses to immunotherapy. This review highlights the biological functions of A-to-I editing, its role in regulating innate immunity and cell death, and its potential molecular significance in tumorigenesis and cancer targeted therapy and immunotherapy.
引用
收藏
相关论文
共 50 条
  • [21] A-to-I RNA editing as a tuner of noncoding RNAs in cancer
    Liao, Yuanfan
    Jung, Seung Ho
    Kim, Taewan
    CANCER LETTERS, 2020, 494 : 88 - 93
  • [22] A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
    Peng, Xinxin
    Xu, Xiaoyan
    Wang, Yumeng
    Hawke, David H.
    Yu, Shuangxing
    Han, Leng
    Zhou, Zhicheng
    Mojumdar, Kamalika
    Jeong, Kang Jin
    Labrie, Marilyne
    Tsang, Yiu Huen
    Zhang, Minying
    Lu, Yiling
    Hwu, Patrick
    Scott, Kenneth L.
    Liang, Han
    Mills, Gordon B.
    CANCER CELL, 2018, 33 (05) : 817 - +
  • [23] Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer
    Zhou, Chi
    Wei, Zhiting
    Zhang, Liye
    Yang, Zhaoyi
    Liu, Qi
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] A-to-I RNA Editing in Cancer: From Evaluating the Editing Level to Exploring the Editing Effects
    Wang, Heming
    Chen, Sinuo
    Wei, Jiayi
    Song, Guangqi
    Zhao, Yicheng
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [25] Systematic characterization of A-to-I RNA editing in cancer development
    Liang, Han
    CANCER RESEARCH, 2018, 78 (13)
  • [26] The roles of ERIANIN in tumor and innate immunity and its' perspectives in immunotherapy
    Yang, Zhen
    Liu, Ruxue
    Qiu, Minghan
    Mei, Hanwei
    Hao, Jie
    Song, Teng
    Zhao, Ke
    Zou, Dandan
    Wang, Huaqing
    Gao, Ming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Metabolic regulation of innate immunity in cancer immunotherapy
    Yuheng Liao
    Hui Yang
    Cancer Biology & Medicine, 2023, (12) : 898 - 902
  • [28] Metabolic regulation of innate immunity in cancer immunotherapy
    Liao, Yuheng
    Yang, Hui
    CANCER BIOLOGY & MEDICINE, 2023, 20 (12) : 898 - 902
  • [29] Cell Death in the Tumor Microenvironment: Implications for Cancer Immunotherapy
    Gadiyar, Varsha
    Lahey, Kevin C.
    Calianese, David
    Devoe, Connor
    Mehta, Dhriti
    Bono, Kristy
    Desind, Samuel
    Davra, Viralkumar
    Birge, Raymond B.
    CELLS, 2020, 9 (10)
  • [30] Stem Cell Origin of Cancer: Clinical Implications for Cancer Immunity and Immunotherapy
    Tu, Shi-Ming
    Aydin, Ahmet Murat
    Maraboyina, Sanjay
    Chen, Zhongning
    Singh, Sunny
    Gokden, Neriman
    Langford, Timothy
    CANCERS, 2023, 15 (22)